Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul;19(4):255-62.
doi: 10.1055/s-0028-1115321.

Sinonasal mucosal melanoma: a 13-year experience at a single institution

Kailash Narasimhan  1 , Omer Kucuk, Ho-Sheng Lin, Lance K Heilbrun, Michael Carron, Raghu Venkatramanamoorthy, Robert Mathog
Affiliations

Sinonasal mucosal melanoma: a 13-year experience at a single institution

Kailash Narasimhan et al. Skull Base. 2009 Jul.

Abstract

Objective: Report the experience of the Karmanos Cancer Institute with sinonasal mucosal melanoma (SNMM) in patients diagnosed between 1995 and 2007.

Results: Eighteen patients, ages 31 to 85 (mean, 67), whose most common presenting symptoms included epistaxis and facial pressure. Most common anatomic locations were the maxillary sinus and nasal cavity. Seventy-two percent presented with tumors extending to the skull base, frontal sinus, orbit, or cranium. Tumor size ranged from 0.3 cm to 5.3 cm. Most common surgical procedure was medial maxillectomy (12 patients). Eight patients received chemotherapy, ten received radiotherapy and six received both. One third of patients received interferon-alpha. Median recurrence-free survival (RFS) was 14.4 months, with a 1-year RFS rate of 55%. Median overall survival (OS) was 19.3 months with a 1-year OS rate of 60% and a 2-year OS rate of 42%. The 5-year OS rate was 34%.

Conclusion: SNMM remains a disease that has eluded breakthroughs in treatment. Patients are typically treated with wide local resection; however unique to our institution was the frequent use of interferon and chemoradiation. Further research in adjuvant therapies will be necessary to improve outcomes.

Keywords: Melanoma; nasal cavity; sinonasal mucosal melanoma; sinus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier graph of recurrence-free survival (RFS) with 90% confidence limits shown as dashed lines. Median RFS was 14.4 months, with 90% confidence interval (CI) of 9.1 to 24.4 months. The 1-year RFS rate was 55%, with 90% CI of 0.32 to 0.78. The 2-year RFS rate was 30%, with 90% CI of 0.08 to 0.52. Three patients were still alive and recurrence-free at 26.1, 29.5, and 30.0 months after surgery.
Figure 2
Figure 2
Kaplan-Meier graph of overall survival (OS) with 90% confidence limits shown as dashed lines. Median OS was 19.3 months, with 90% confidence interval (CI) 9.1 to 107.3 months. The 2-year OS rate was 42%, with 90% CI 0.20 to 0.64. The 5-year OS rate was 34%, with 90% CI 0.12 to 0.57. Two patients are currently still alive at 74.4 and 103.4 months after surgery.
See this image and copyright information in PMC

References

    1. Thompson A C, Morgan D A, Bradley P J. Malignant melanoma of the nasal cavity and paranasal sinuses. Clin Otolaryngol. 1993;18:34–36. - PubMed
    1. Conley J J, Ackerman A B. Melanoma of the Head and Neck. 1st ed. New York: Georg Thieme Verlag; 1990. pp. 154–178.
    1. Thompson L DR, Wienke J A, Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol. 2003;27(5):594–611. - PubMed
    1. Cheng Y F, Lai C C, Ho C Y, Shu C H, Lin C Z. Toward a better understanding of sinonasal mucosal melanoma: clinical review of 23 cases. J Chin Med Assoc. 2007;70(1):24–29. - PubMed
    1. Lee E. Statistical Methods for Survival Data Analysis. 3rd ed. Hoboken, New Jersey: Wiley & Sons, Inc.; 2003. pp. 76–91.